Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Dyspareunia is Associated With Chronic Pain in Premenopausal Women With Sickle Cell Disease
source: Hematology
year: 2018
authors: Karafin MS, Singh M, Ceesay M, Koduri S, Zhang L, Simpson P, Field JJ
summary/abstract:Objectives:
Pain is common in women with sickle cell disease (SCD), but the prevalence of dyspareunia in this unique patient population is unknown. In this study, we sought to determine whether chronic pain is associated with an increased prevalence of dyspareunia in premenopausal women with SCD.
Methods:
A cross-sectional study of premenopausal women with SCD was systematically assessed for symptoms of dyspareunia and chronic pain using a standard questionnaire. These results were correlated with each subject’s clinical pain phenotype determined by a review of the patient’s electronic medical record.
Results:
Ninety-one premenopausal women with SCD were examined. Thirty-two percent of the women reported dyspareunia. Women with dyspareunia were more likely to have a history of chronic pain (90% versus 61%, p = .006), report more pain days per week (median (interquartile range): 6 (4-7) vs. 3 (0-7), p = .005)), and had a higher oral morphine equivalent dose (145 (45-226) mg vs. 60 (9-160) mg, p = .030). Using a multivariable classification tree analysis, number of days of pain experienced per week was an important predictor of dyspareunia (p = .001).
Conclusion:
Dyspareunia is common in women with SCD, and more common in women with SCD and chronic pain. Providers should assess women with SCD for dyspareunia, especially those with a chronic pain syndrome.
organization: Blood Center of Wisconsin, USA; Medical College of Wisconsin, USADOI: 10.1080/10245332.2018.1430521
read more full text
+myBinderRelated Content
-
Mechanisms of Pain in Sickle Cell DiseaseObjectives: The hallmark of sickle cell...
-
Characteristics of a Chronic Pain Phenotype in Adults with Sickle Cell DiseaseSickle cell disease (SCD) is characteriz...
-
APS Scientific Meeting 2019The American Pain Society will hold its ...
-
Vaso occlusive Crisis Pain Assessment & Managementhttps://www.youtube.com/watch?time_conti...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
Gut Microbiome Translates Stress Into Sickle Cell CrisesA new study shows how chronic psychologi...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
Don’t forget to join the oneSCDvoice community!
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.
